Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

SABCS 2016 PR
Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016 December 5, 2016
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its products at the San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas, from December 6-10, 2016.
For more information about the SABCS meeting and for a complete list of abstracts, please refer to the conference website at http://www.abstracts2view.com/sabcs/.
The following are key ROLONTISTM (eflapegrastim) related abstracts being presented at the SABCS meeting:
Abstract # Type Title First Author Date/Time
Location: Hall 1
OT1-01-11 Poster Randomized phase 3 study of a novel, long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study)
Schwartzberg Wednesday, Dec 7
5:00 PM
P5-11-09 Poster Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study
Vacirca Friday, Dec 9
5:00 PM
P5-11-07 Poster Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen
Vacirca Friday, Dec 9
5:00 PM
P5-11-08 Poster Immunogenicity of eflapegrastim in a Phase 2 Open-Label Dose-Ranging Study of eflapegrastim in Breast Cancer Patients Receiving TC Regimen
Vacirca Friday, Dec 9
5:00 PM
The following key poziotinib related abstract will be presented at the SABCS meeting:
Abstract # Type Title First Author Date/Time
Location: Hall 1
OT1-02-10 Poster A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC